Panel COVERS Problems With Cephalon’s Fentora
This article was originally published in The Pink Sheet Daily
Executive Summary
Risk-management plan is “impressive,” but needs supporting evidence, FDA advisors say.
You may also be interested in...
Pain Therapeutics’ Remoxy Approval Hinges On REMS; FDA Unsure If Drug Is Abuse-Resistant
FDA’s Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees will discuss whether the proposed REMS can adequately determine abuse of the opioid.
Pain Therapeutics’ Remoxy Approval Hinges On REMS; FDA Unsure If Drug Is Abuse-Resistant
FDA’s Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees will discuss whether the proposed REMS can adequately determine abuse of the opioid.
FDA Advisors Will Review Abuse-Resistant Remoxy And Embeda
Pain drugs may face safety review similar to Cephalon’s Fentora.